Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Study of Roginolisib in Combination With Dostarlimab With or Without Docetaxel in Patients With Advanced Non-squamous NSCLC Who Have Progressed on Standard of Care Immune Checkpoint Therapy and Platinum Doublet Chemotherapy or Standard Immunotherapy Without Chemotherapy (PULMO-1)

NCT06879717 is registered in ClinicalTrials.gov with iOnctura as lead sponsor.

NCT NCT06879717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06879717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Study of Roginolisib in Combination With Dostarlimab With or Without Docetaxel in Patients With Advanced Non-squamous NSCLC Who Have Progressed on Standard of Care Immune Checkpoint Therapy and Platinum Doublet Chemotherapy or Standard Immunotherapy Without Chemotherapy (PULMO-1)
Lead sponsor
iOnctura
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 22, 2025
Completion date
January 31, 2028
Enrollment
45 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non squamous nsclc, non-squamous non-small cell lung cancer (nsclc)